Katayoun Motlagh, MD
Family Medicine · Lancaster, CANPI 1457553620
Payments from drug & device makers
Across 339 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$985
- AstraZeneca$697
- Bristol Myers Squibb$530
- Novo Nordisk$501
- Lilly USA, LLC$335
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,38197%
- Education$1983%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 89 | $1,511 |
| AbbVie(2 entities) | 42 | $985 |
| AstraZeneca | 27 | $697 |
| Bristol Myers Squibb | 24 | $530 |
| Novo Nordisk | 31 | $501 |
| Lilly USA, LLC | 20 | $335 |
| Galderma Laboratories, L.p. | 5 | $281 |
| Amarin Pharma, Inc. | 14 | $279 |
| Pfizer | 11 | $221 |
| Boehringer Ingelheim | 12 | $208 |
| Axsome Therapeutics, Inc. | 3 | $187 |
| Medicure Pharma Inc. | 3 | $171 |
| Merz North America, Inc. | 2 | $166 |
| Aimmune Therapeutics, Inc. | 3 | $151 |
| Phathom Pharmaceuticals, Inc. | 1 | $141 |
| Astellas Pharma US Inc | 4 | $137 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 5 | $109 |
| Mayne Pharma Commercial LLC | 1 | $105 |
| Johnson & Johnson | 1 | $100 |
| GSK | 6 | $91 |
| Otsuka America Pharmaceutical, Inc. | 5 | $84 |
| Nestle Healthcare Nutrition Inc. | 6 | $75 |
| Kowa Pharmaceuticals America, Inc. | 3 | $60 |
| Lundbeck LLC | 3 | $49 |
| Ultragenyx Pharmaceutical Inc. | 2 | $44 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| IBSA Pharma Inc. | 2 | $35 |
| Radius Health, Inc. | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 2 | $29 |
| Novartis | 1 | $20 |
| Corcept Therapeutics | 1 | $18 |
| Merck | 1 | $16 |
| Dexcom, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $12 |
| Alfasigma USA, Inc. | 1 | $11 |
| Optos, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,580 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 99 | $94,770 |
| MounjaroTirzepatide | 55 | $70,185 |
| OzempicSemaglutide | 54 | $51,050 |
| TrulicityDulaglutide | 29 | $46,377 |
| TradjentaLinagliptin | 53 | $44,909 |
| LinzessLinaclotide | 34 | $39,217 |
| VascepaIcosapent Ethyl | 40 | $25,326 |
| JardianceEmpagliflozin | 30 | $23,872 |
| MyrbetriqMirabegron | 37 | $20,018 |
| RybelsusSemaglutide | 13 | $17,533 |
| EliquisApixaban | 13 | $16,150 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $15,589 |
| EntrestoSacubitril/Valsartan | 17 | $13,684 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $10,009 |
| Pitavastatin Calcium | 46 | $9,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $335 | $116,56284 claims |
| AstraZenecaFarxiga | $697 | $94,77099 claims |
| Boehringer IngelheimTradjenta, Jardiance | $208 | $68,78183 claims |
| Novo NordiskOzempic, Rybelsus | $501 | $68,58367 claims |
| AbbVieLinzess | $985 | $39,21734 claims |
| PfizerEliquis, Premarin | $221 | $24,17328 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $91 | $23,49524 claims |
| Astellas Pharma US IncMyrbetriq | $137 | $20,01837 claims |
| NovartisEntresto | $20 | $13,68417 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $60 | $7,55712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Lancaster
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.